Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 15/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802981 | 1.00 | PTGIR (0.52) | PTGIRPTGDRTBXA2R | |
| SCHEMBL6802991 | 1.00 | PTGIR (0.52) | PTGIRPTGDRTBXA2R | |
| SCHEMBL14265713 | 0.92 | PTGIR (0.50) | PTGIRPTGDRTBXA2R | |
| SCHEMBL6316993 | 0.91 | PTGIR (0.49) | PTGIRPTGDRTBXA2R | |
| SCHEMBL6316987 | 0.91 | PTGIR (0.49) | PTGIRPTGDRTBXA2R | |
| SCHEMBL14286249 | 0.87 | PTGIR (0.50) | PTGIRPTGDRTBXA2R | |
| SCHEMBL6797753 | 0.87 | SIRT1 (0.44) | PTGIR | |
| SCHEMBL6797758 | 0.87 | SIRT1 (0.44) | PTGIR | |
| SCHEMBL6797764 | 0.87 | SIRT1 (0.44) | PTGIR | |
| SCHEMBL27576353 | 0.82 | PTGIR (0.44) | PTGIRPTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809095-B2 | NOVEL ANTITOBESITY AND HYPOCHOLESTEROLEMIC COMPOUNDS LOWER TOTAL CHOLESTEROL; INCREASE HIGH DENSITY LIPOPROTEIN (HDL) AND DECREASE LOW DENSTIY LIPOPROTEIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-26 | — | — | US | claimed |
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY-CHEMINOR, INC. | 2001-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CPT1A, GPR119, SLC5A1 | PTGIR 665/4885PTGDR 1747/4885TBXA2R 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.